The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
Official Title: Phase II Clinical Evaluation of Bryostatin 1 in Patients With Myelodysplastic Syndrome
Study ID: NCT00003171
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with myelodysplastic syndrome.
Detailed Description: OBJECTIVES: I. Determine the response rate of bryostatin 1 in patients with myelodysplastic syndrome. II. Determine the qualitative and quantitative toxic effects of bryostatin 1. III. Determine the duration of response and survival of patients receiving this therapy. OUTLINE: This is a two stage study. Patients receive bryostatin 1 by continuous infusion over 72 hours every 14 days for 4 cycles. Responding patients may continue treatment in the absence of disease progression or unacceptable toxicity. Patients with complete response receive 2 additional cycles. Patients with no response receive 4 additional cycles. Patients are re-evaluated after every 4 cycles. PROJECTED ACCRUAL: 14 to 27 patients will be accrued within 2 years into this 2 stage study.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Name: Ayad M. Al-Katib, MD, FACP
Affiliation: Barbara Ann Karmanos Cancer Institute
Role: STUDY_CHAIR